General Toxicity Notes
May decrease renal function. Decrease platelet aggregation. Nephrotic syndrome, interstitial nephritis, hyperkalemia, sodium retention.
Half-Life (Normalesrd) Hours
50-60/Unchanged
Plasma Protein Binding %
>99
Volume Of Distribution L/Kg
0.2
Dose For Normal Renal Function
1200 mg q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable
References
Davies NM. Clinical pharmacokinetics of oxaprozin. Clin Pharmacokinet. 1998; 35: 425-36. [PMID: 9884815]